Three hundred adults with severe aortic stenosis undergoing valve replacement were randomized to receive the Epic ( St Jude , St Paul , Minn ) ( n = 99 ) , Magna ( Edwards LifeSciences Inc , Irvine , Calif ) ( n = 100 ) , or Mitroflow ( Sorin Biomedica Spa , Saluggio , Italy ) ( n = 101 ) bioprostheses .